Company overview
Stellaromics offers the Pyxa platform, the first commercial system for high-plex 3D spatial multi-omics in intact tissue up to 100 micrometers thick. It enables subcellular-resolution mapping of gene expression, proteins, and active translation using technologies like STARmap, RIBOmap, and STARmap PLUS. The integrated solution includes sample preparation, automated confocal imaging, and PyxaStudio software for visualization and analysis, supporting pharma R&D in resolving complex tissue organization and disease mechanisms.
Stellaromics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include 3d spatial multi-omics, pyxa platform, spatial transcriptomics, thick tissue imaging, starmap.
Structured facts
- Website
- https://stellaromics.com
- Markets served
- United States & Americas
- Keywords
- 3d spatial multi-omics, pyxa platform, spatial transcriptomics, thick tissue imaging, starmap
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What capabilities does the Pyxa platform offer?
- Pyxa provides high-plex confocal imaging for 3D spatial multi-omics, capturing single-cell gene expression, proteins, and translation in intact tissue up to 100 µm thick with subcellular detail and custom panels.
- What technologies power Stellaromics' spatial analysis?
- The platform uses STARmap for transcripts, RIBOmap for active translation, and STARmap PLUS for proteins, enabling multi-omic analysis while preserving native 3D tissue structure.
- Where is Stellaromics located and who founded it?
- Headquartered in Boston, Massachusetts, USA, Stellaromics was spun out from labs of Karl Deisseroth (Stanford) and Xiao Wang (MIT/Broad Institute).
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
